In the section "Monday June 6, 8:00 a.m. to noon CT., Hall A" the Abstract No. should be 3053 (sted 4023).
The corrected release reads:
RESPONSE GENETICS ANNOUNCES PRESENTATION OF LUNG CANCER AND ESOPHAGEAL CANCER STUDY RESULTS AT 2011 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
New Data Support Use of Cancer Biomarkers for Patient Screening and Treatment SelectionResponse Genetics, Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, announced today five presentations to be held during the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 3 to June 7, 2011. Study results are based in part on the company’s proprietary technology and approach. Data will highlight clinical results in non-small cell lung cancer (NSCLC) and esophageal cancer and approaches to improve cancer care. “The results to be presented at ASCO 2011 are the product of Response Genetics’ commitment to finding new ways to help patients and to personalize cancer care,” said Kathleen Danenberg, CEO of Response Genetics. “Through scientific and clinical collaborations we are applying our powerful technology to identify lung cancer patients likely to benefit from new and existing therapies and to investigate the use of predictive and prognostic markers in the treatment of esophageal cancers.” All studies presented used technology developed by Response Genetics to isolate RNA from formalin-fixed, paraffin-embedded (FFPE) archived tissue for quantitative RT-PCR analysis of gene expression. Following is a summary of presentations: Poster Discussion Sections Saturday June 4, 5:00 p.m. to 6:00 p.m. CT., S 100bc Abstract No. 10520: Large-scale screening of ALK fusion oncogene transcripts in archival NSCLC tumor specimens using multiplexed RT-PCR assays. A panel of single and multiplexed RT-PCR assays capable of detecting all nine known EML4-ALK fusion gene transcripts and ALK RNA level variants was used to identify ALK-positive patients and to investigate the impact of crizotinib on tumor sensitivity to chemotherapy. Of the 1,889 NSCLC specimens tested, 75 (4.0 percent) were EML4-ALK positive – all were adenocarcinomas and none harbored EGFR or K-Ras mutations. This unique approach allows the rapid, large-scale screening of NSCLC tissues for ALK fusion gene transcripts.